Overview
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is characterized by hyponatremia with hyposmolarity, euvolemia, and inappropriately concentrated urine, despite normal or low levels of antidiuretic hormone (AVP). It results from dysfunctional vasopressin V2 receptor signaling, leading to impaired water reabsorption in the kidney 1.Diagnosis
Key Criteria: Prolonged euvolemic hyponatremia, hypo-osmolarity, concentrated urine, elevated natriuresis, and normal/low or undetectable AVP levels 1.
Recommended Tests: Molecular analysis of the V2R receptor gene to detect mutations such as R137C 1.
Evaluation: Distinguish from central DI by measuring AVP levels and assessing clinical context 1.Management
First-Line Treatment: Thiazide diuretics to enhance sodium reabsorption and promote water excretion 1.
Adjunctive Treatments: Hypertonic saline for severe hyponatremia correction under close monitoring 1.
Avoid: Nonspecific vasopressin receptor agonists due to potential lack of efficacy in NSIAD 1.Special Populations
Pediatrics: NSIAD can manifest neonatally; molecular testing of V2R receptor is crucial in neonates with persistent euvolemic hyponatremia 1.Key Recommendations
Perform molecular analysis of the V2R receptor gene in neonates presenting with prolonged euvolemic hyponatremia, hypo-osmolarity, and normal/low AVP levels (Evidence: Strong 1).
Consider thiazide diuretics as first-line therapy for managing NSIAD (Evidence: Moderate 1).
Closely monitor and correct severe hyponatremia with hypertonic saline in NSIAD patients (Evidence: Expert opinion 1).References
1 Marcialis MA, Faà V, Fanos V, Puddu M, Pintus MC, Cao A et al.. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatric nephrology (Berlin, Germany) 2008. link